Korean J Hematol.  2010 Dec;45(4):286-286. 10.5045/kjh.2010.45.4.286.

Concerns in assessing risk factors for herpes zoster infection in multiple myeloma patients

• Lee DG

• KMID: 2252044
• DOI: http://doi.org/10.5045/kjh.2010.45.4.286

Abstract

No abstract available.

MeSH Terms

Herpes Zoster
Humans
Multiple Myeloma
Risk Factors

Reference

1. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009; 49:1211–1225. PMID: 19769539.

2. Yi YS, Chung JS, Song MK, et al. The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol. 2010; 45:188–192. PMID: 21120208.

3. Choi WS, Noh JY, Huh JY, et al. Seroprevalence of varicella-zoster virus in Korea. J Med Virol. 2010; 82:2123–2126. PMID: 20981803.

4. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26:4784–4790. PMID: 18711175.

5. Dasanu CA, Alexandrescu DT. Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma? J Clin Oncol. 2009; 27:2293–2294. PMID: 19307496.